Company: LIMN
Filing Date: 2025-07-28
Form Type: S-1/A
Source: 0001410578-25-001518
Chunk: 2

Company: Liminatus Pharma, Inc.
Filing Date: 2025-07-28
Form: S-1/A
Chunk 2
---
 shares were issued at a deemed value of $10.00 per share pursuant to the terms of the Business Combination Agreement (as defined below); (b) 6,900,000 shares of Common Stock issued to the Sponsor (as defined below) upon conversion of the founder shares issued to the Sponsor prior to the IPO (as defined below), which shares were purchased by the Sponsor at a price per share of $0.004; (c) 1,500,000 shares of Common Stock issued to PIPE Investor (as defined below) pursuant to the PIPE Equity Subscription Agreement (as defined below); (d) 835,555 shares of Common Stock issuable upon the exercise of 835,555 private warrants (the “Private Warrants”), which were originally issued concurrently with the IPO in a private placement to Cantor (as defined below) at a price of $1.50 per warrant, with each warrant exercisable for one share of Common Stock at $11.50 per share; (e) up to 700,000 shares of Common Stock issued to Cantor in settlement of $7.0 million in deferred underwriting fees; and (f) up to 350,000 shares of Common Stock issued to Alta Partners, LLC (“Alta”) pursuant to a settlement and release agreement. See “Selling Securityholders” for the details of these securities. In addition, this prospectus relates to the issuance by us of up to 6,900,000 shares of Common Stock that are issuable upon the exercise of the public warrants at an exercise price per share of $11.50 (the “Public Warrants,” and together with the Private Warrants, the “Warrants”) contained in the units sold at a price of $10.00 per unit in the IPO. The Selling Securityholders may offer, sell or distribute all or a portion of the securities hereby registered publicly or through private transactions at prevailing market prices or at negotiated prices. We will not receive any of the proceeds from such sales of the shares of their Common Stock. On July 23, 2025, the last reported sales price of our Common Stock was $6.47. The exercise price per share of the Warrants is $11.50, which is higher than the current market price of our Common Stock and accordingly, Warrant holders may not be able to exercise their Warrants at this time. Cash proceeds associated with the exercises of the Warrants are dependent on our stock price and given the recent price volatility of our Common Stock